Gemcitabine injection to prevent bladder cancer recurrence
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether injecting gemcitabine into the bladder lining during tumor removal surgery can help prevent the cancer from coming back in people with intermediate- or high-risk non-muscle-invasive bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with a bladder tumor and are scheduled for surgery to remove it.
- After surgery, the tumor is confirmed as intermediate- or high-risk non-muscle-invasive bladder cancer.
- You do not have other bladder or urinary problems like overactive bladder, strictures, or incontinence.
- You do not have an active urinary infection.
- You have not had pelvic radiation therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.